Nass, Sharyl J.
Rothenberg, Mace L.
Pentz, Rebecca
Hricak, Hedvig
Abernethy, Amy
Anderson, Kenneth
Gee, Amanda Wagner
Harvey, R. Donald
Piantadosi, Steven
Bertagnolli, Monica M.
Schrag, Deborah
Schilsky, Richard L.
Article History
First Online: 1 October 2018
Competing interests
: S.J.N. receives partial salary support from the sponsors of the National Cancer Policy Forum. M.L.R. is an employee and stockholder of Pfizer. H.H. is a member of the board of directors of Ion Beam Applications. A.A. is an employee of Flatiron Health. K.A. is an advisory board member for Bristol-Myers Squibb (BMS), Celgene and Millennium Takeda, a scientific advisory board member of Gilead, and the National Cancer Institute and is a founder of C4 Therapeutics and Oncopep. A.W.G. receives salary support from the sponsors of the National Academies of Sciences, Engineering and Medicine (NASEM) Forum on Drug Discovery, Development and Translation. R.D.H. receives research funding that supports his salary from Abbvie, Amgen, Arqule, AstraZeneca, BMS, Calithera, Celgene, Corvus, Eli Lilly, Five Prime Therapeutics, Genmab, Halozyme, Ignyta, Incyte, Merck, Nektar, Pfizer, Regeneron, Rgenix, Sanofi, Syndax, Takeda and Vertex. R.L.S. is a principal investigator in the Targeted Agent and Profiling Utilization Registry (TAPUR) study, which receives grant support from AstraZeneca, Bayer, BMS, Genentech, Lilly, Merck and Pfizer. R.P., S.P., M.M.B. and D.S. declare no competing interests.